医疗补助扩大对妇科癌症女性的影响:双重差分分析
调整模型显示无保险率降低2.00%,早期诊断、学术机构治疗、30天内治疗和30天内手术分别增加0.80%、0.83%、1.62%和1.54%。
要点
- 医疗补助扩大与诊断时无保险率降低2.00%相关(95%CI -2.3至-1.7,P<.001)。
- 早期诊断增加0.80%(95%CI 0.2-1.4,P=.02),学术机构治疗增加0.83%(95%CI 0.1-1.5,P=.02)。
- 30天内治疗和30天内手术分别增加1.62%(95%CI 1.0-2.3)和1.54%(95%CI 0.8-2.3),均P<.001。
核心结论
- 医疗补助扩大与非老年妇科癌症女性在获得诊疗和诊疗及时性方面的改善显著相关。
- 实施医疗补助扩大可能使未扩大州的女性大为受益。
- 作者认为妇科医生和妇科肿瘤医生应倡导医疗补助扩大,以改善结局并减少社会经济和种族差异。
研究设计与样本
- 准实验回顾性队列研究,使用国家癌症数据库2008至2016年诊断为子宫、卵巢和输卵管、宫颈、阴道及外阴浸润性癌的女性。
- 样本共335,063例,其中未扩大州121,449例,扩大州213,614例,扩大州医疗补助扩大完全生效后诊断的病例79,886例。
- 排除年龄<40岁女性(因数据中州医疗补助扩大状态被抑制)和年龄≥65岁女性(因普遍享有 Medicare 覆盖)。
- 采用双重差分模型评估医疗补助扩大对诊疗可及性和及时性的影响,并在多个亚组和倾向性匹配队列中验证稳健性。
- 使用事件研究时间图评估平行趋势假设。
主要发现
- 基本双重差分模型中,2014年1月医疗补助扩大与诊断时有保险、学术机构治疗及30天内治疗显著增加相关(均P<.001)。
- 调整模型(含所有州并考虑扩大实施时间差异)显示,医疗补助扩大使诊断时无保险率降低2.00%(95%CI -2.3至-1.7,P<.001)。
- 早期诊断增加0.80%(95%CI 0.2-1.4,P=.02),学术机构治疗增加0.83%(95%CI 0.1-1.5,P=.02)。
- 30天内治疗增加1.62%(95%CI 1.0-2.3,P<.001),30天内手术增加1.54%(95%CI 0.8-2.3,P<.001)。
- 低收入邮编地区女性、西班牙裔女性和宫颈癌女性的估计获益较大;除早期诊断和30天内治疗外,亚组和倾向性匹配队列估计与主要结果基本一致。
临床怎么用
- 作者认为妇科医生和妇科肿瘤医生应倡导医疗补助扩大,以改善结局并减少社会经济和种族差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women with gynecologic cancer face socioeconomic disparities in care that affect survival outcomes. The Affordable Care Act offered states the option to expand Medicaid enrollment eligibility criteria as a means of improving timely and affordable access to care for the most vulnerable. The variable uptake of expansion by states created a natural experiment, allowing for quasi-experimental methods that offer more unbiased estimates of treatment effects from retrospective data than the traditional regression adjustment. OBJECTIVE: To use a quasi-experimental, difference-in-difference framework to create unbiased estimates of impact of Medicaid expansion on women with gynecologic cancer. STUDY DESIGN: We performed a quasi-experimental retrospective cohort study from the National Cancer Database files for women with invasive cancers of the uterus, ovary and fallopian tube, cervix, vagina, and vulva diagnosed from 2008 to 2016. Using a marker for state Medicaid expansion status, we created difference-in-difference models to assess the impact of Medicaid expansion on the outcomes of access to and timeliness of care. We excluded women aged <40 years owing to the suppression of the state Medicaid expansions status in the data and women aged ≥65 years owing to the universal Medicare coverage availability. Our primary outcome was the rate of uninsurance at diagnosis. Secondary outcomes included Medicaid coverage, early-stage diagnosis, treatment at an academic facility, and any treatment or surgery within 30 days of diagnosis. Models were run within multiple subgroups and on a propensity-matched cohort to assess the robustness of the treatment estimates. The assumption of parallel trends was assessed with event study time plots. RESULTS: Our sample included 335,063 women. Among this cohort, 121,449 were from nonexpansion states and 213,614 were from expansion states, with 79,886 posttreatment cases diagnosed after the expansion took full effect in expansion states. The groups had minor differences in demographics, and we found occasional preperiod event study coefficients diverging from the mean, but the outcome trends were generally similar between the expansion and nonexpansion states in the preperiod, satisfying the necessary assumption for the difference-in-difference analysis. In a basic difference-in-difference model, the Medicaid expansion in January 2014 was associated with significant increases in insurance at diagnosis, treatment at an academic facility, and treatment within 30 days of diagnosis (P<.001 for all). In an adjusted model including all states and accounting for variable expansion implementation time, there was a significant treatment effect of Medicaid expansion on the reduction in uninsurance at diagnosis (-2.00%; 95% confidence interval, -2.3 to -1.7; P<.001), increases in early-stage diagnosis (0.80%; 95% confidence interval, 0.2-1.4; P=.02), treatment at an academic facility (0.83%; 95% confidence interval, 0.1-1.5; P=.02), treatment within 30 days (1.62%; 95% confidence interval, 1.0-2.3; P<.001), and surgery within 30 days (1.54%; 95% confidence interval, 0.8-2.3; P<.001). In particular, large gains were estimated for women living in low-income zip codes, Hispanic women, and women with cervical cancer. Estimates from the subgroup and propensity-matched cohorts were generally consistent for all outcomes besides early-stage diagnosis and treatment within 30 days. CONCLUSION: Medicaid expansion was significantly associated with gains in the access and timeliness of treatment for nonelderly women with gynecologic cancer. The implementation of Medicaid expansion could greatly benefit women in nonexpansion states. Gynecologists and gynecologic oncologists should advocate for Medicaid expansion as a means of improving outcomes and reducing socioeconomic and racial disparities.
引用
- Albright BB, Nasioudis D, Craig S, et al. Impact of Medicaid expansion on women with gynecologic cancer: a difference-in-difference analysis. Am J Obstet Gynecol. 2020. PMID: 32777264. doi:10.1016/j.ajog.2020.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。